Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $250M | $388M | $551M | $745M | $767M | $750M | $792M | $797M |
| Revenue growth | — | 55.6% | 41.9% | 35.4% | 2.8% | -2.1% | 5.6% | 0.6% |
| Operating income | $77.3M | $140M | -$276M | $13.4M | $1.74M | -$27.0M | $65.8M | $87.5M |
| Operating margin | 31.0% | 36.0% | -50.1% | 1.8% | 0.2% | -3.6% | 8.3% | 11.0% |
| Net income | $43.8M | $66.0M | -$294M | -$25.3M | -$32.8M | -$8.87M | $16.4M | $30.4M |
| Net margin | 17.6% | 17.0% | -53.3% | -3.4% | -4.3% | -1.2% | 2.1% | 3.8% |
| EPS (diluted) | $0.12 | $0.18 | -$1.07 | -$0.06 | -$0.08 | -$0.02 | $0.04 | $0.09 |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $45.3M | $83.3M | $131M | $179M | $147M | $138M | $184M | $168M |
| Capital expenditures | $804K | $1.43M | $20.6M | $4.57M | $3.97M | $1.04M | $1.24M | $3.52M |
| Free cash flow | $44.4M | $81.9M | $111M | $174M | $143M | $137M | $183M | $164M |
| Share buybacks | — | — | $0.00 | $0.00 | $102M | $104M | $159M | $216M |
| Dividends paid | $1.35B | — | — | — | — | — | — | — |
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $34.6M | $26.1M | $969M | $941M | $757M | $672M | $448M | $262M |
| Total assets | — | $387M | $1.47B | $1.61B | $1.60B | $1.59B | $1.39B | $1.40B |
| Total liabilities | — | $737M | $759M | $776M | $790M | $827M | $663M | $788M |
| Long-term debt | — | $664M | $660M | $656M | $652M | $648M | $487M | $483M |
| Shareholders' equity | -$1.16B | -$1.09B | $711M | $832M | $815M | $762M | $725M | $616M |
| Retained earnings | — | -$1.10B | -$1.39B | -$1.42B | -$1.45B | -$1.46B | -$1.44B | -$1.41B |
| Shares (wtd avg diluted) | 118M | 231M | 275M | 410M | 413M | 410M | 392M | 357M |
Every figure is extracted from GoodRx Holdings, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.